SEC Form 4 · accession 0001213529-17-000007
Zosano Pharma Corp · ZSAN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Peter Walker
Officer — President and CEO · Director
Period of report
Aug 9, 2017
Accepted (ET)
Aug 11, 2017 · 7:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001587221
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 9, 2017 | D | 26,666 | $0.00 | D | 180,228 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $0.99 | Aug 9, 2017 | A | 300,000 | A | — | Aug 9, 2027 | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F1The common stock was granted subject to vesting on May 18, 2017. A total of 33,334 shares have vested as of August 9, 2017, and the remaining 26,666 shares have been forfeited.
- F225% of the total number of shares underlying the stock option vest on August 9, 2018, and the remaining underlying shares vest in equal monthly installments over the following three-year period, so that all shares have vested on August 9, 2021.